

 **RUSSIAN DIRECT**
INVESTMENT FUND
Joint Stock Company
«Management Company of Russian Direct
Investment Fund»
Capital City, South Tower, 7th floor
Presnenskaya emb., 8/1, Moscow, Russia 123112
Tel.: +7 (495) 644-3414, Fax: +7 (495) 644-3413

Mr. Fernando de Castro Marques
President of the Uniao Quimica Group

04.02.2021 № 157/02-21

Supply of the vaccines to Brazil

Date: 04 February 2021

Dear Mr. Marques,

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) hereby confirms its strong intention to get authorization of the "Sputnik V" human adenovirus vector vaccine ("Vaccine") in Brazil and supply up to 5 million people treatments (equal to 10 million doses, 2 doses for each treatment) to the country according to the following schedule:

- 1) 200 thousand people treatments the next week following authorization of the Sputnik V's use in Brazil,
- 2) 1 million people treatments – in one month following authorization,
- 3) 3.8 million people treatments – during the second and the third month following authorization.

In addition to Sputnik V, within several months RDIF will also be ready to deliver another vaccine to Brazil – "Sputnik Light", a single-component vaccine comprised of the first shot of "Sputnik V". Based on the Russian clinical trials data, efficacy of "Sputnik Light" accounts for 75-80%, which is higher than efficacy of all vaccines authorized in Brazil now. Upon the regulator's request, we are also ready to explore possibility to conduct Phase 3 clinical trials of "Sputnik Light" in Brazil.

For your reference, we also would like to confirm that the two available storage regimens of the "Sputnik V" vaccine (+2+8°C for up to 2 months and -18°C for up to 8 months) are applied to the same vaccine without any difference in its chemical formula or manufacturing process.

Sincerely,



Kirill Dmitriev
CEO